SLC46A3 Knockout Cell Line (HEK293)

The choice depends on whether you are studying SLC46A3's role as a lysosomal transporter critical for antibody-drug conjugate (ADC) efficacy or its emerging endogenous functions as a proton-coupled steroid conjugate and bile acid transporter. The Knockout line is the standard tool for asking whether SLC46A3 is required for releasing noncleavable ADC catabolites from the lysosome to the cytoplasm — SLC46A3 directly transports Lys-SMCC-DM1 (the major catabolite of trastuzumab emtansine/T-DM1) and is a critical determinant of T-DM1 efficacy. Overexpression is useful for studying mechanisms of restoring ADC sensitivity in resistant cells. For ADC research, the EDITGENE SLC46A3 Knockout in HEK293 is a highly relevant mechanistic platform — SLC46A3 loss is a defined mechanism of innate and acquired resistance to maytansine-based (DM1) and pyrrolobenzodiazepine (PBD/SG3376) noncleavable ADCs, with patient relevance as a predictive biomarker. Rescue with wild-type SLC46A3 restores ADC sensitivity in resistant lines — this rescue paradigm is established in the literature. Rescue with transport-deficient variants enables structure-function studies.

Primary applications: • ADC cytotoxicity assays: assessment of T-DM1, SG3376, and other noncleavable ADC potency in SLC46A3-null versus rescued cells — this knockout-rescue paradigm is established for predicting ADC efficacy. • Lysosomal catabolite retention: lysosomal extraction and mass spectrometry analysis of Lys-SMCC-DM1 and other ADC catabolites to demonstrate SLC46A3-dependent cytoplasmic release. • Endogenous substrate studies: bile acid and steroid conjugate transport assays — SLC46A3 has been characterized as a proton-coupled steroid conjugate/bile acid transporter. • Biomarker validation: studies of SLC46A3 expression as a predictive biomarker for ADC patient selection. EDITGENE recommends this model for researchers in ADC development, mechanisms of ADC resistance, and lysosomal transporter biochemistry.

Yes. SLC46A3 rescue experiments are well-established in ADC research: • Construct design: use a codon-modified SLC46A3 sequence with a small C-terminal tag (FLAG, HA). SLC46A3 is a lysosomal membrane protein — small tags and proper lysosomal targeting signals must be preserved. • Lysosomal localization validation: confirm lysosomal localization of exogenous SLC46A3 by LAMP1 co-staining before ADC sensitivity assays. • Transport-deficient rescue: substrate-binding mutations enable distinguishing ADC catabolite transport from non-transport functions. • Functional readout: rescue should restore T-DM1 cytotoxicity — sensitivity restoration in resistant lines is the established positive control. Lysosomal Lys-SMCC-DM1 retention by mass spectrometry confirms transport function rescue. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for ADC sensitivity studies.